**Core tip:** Without liver transplant, patients with cirrhosis have 50% mortality at 5 years; these patients represent a population that would benefit from palliative care services. Palliative care services are grossly underutilized in older, non-white patients with cirrhosis on the liver transplant wait-list. We encourage early integration of these services into clinical decision-making in the transplant population, with further studies aimed at understanding barriers to consultation.

INTRODUCTION
============

Decompensated cirrhosis is characterized by ascites, hepatic encephalopathy, and variceal bleeding. Mortality is high with 50% death rate due to complications of cirrhosis within five years\[[@B1],[@B2]\]. In addition to these medical complications, patients with decompensated cirrhosis experience a large symptomatic burden including debilitating fatigue, muscle wasting, anorexia, and intractable pruritus. Self-reported quality of life is poor in cirrhotics; in one study, 38% of elderly patients with cirrhosis had difficulty in independently completing at least one daily living activity including dressing, walking few steps, or bathing while 10% had impaired integral activities of daily living (*i.e*., managing money, cooking, grocery shopping)\[[@B3]-[@B5]\]. Their physical symptoms, inability to independently care for themselves, and knowledge of their terminal disease often erodes their emotional and psychological well-being.

While it is clear that liver transplantation is essentially the only known cure for complications of end-stage liver disease, the ability to receive a transplant can be unpredictable: One in five individuals awaiting liver transplantation will die on the waitlist\[[@B6]\]. While the process of listing individuals for liver transplantation is highly structured through formal medical, surgical, social, and psychological evaluations, there is no standard of care for the process to transition those who are deemed too sick for liver transplantation to comfort care. We aimed to evaluate current utilization of palliative care services in liver transplant candidates who did not survive to liver transplant and understand which patient characteristics are associated with palliative care consultation in this population.

MATERIALS AND METHODS
=====================

All adult cirrhotic patients who were newly listed for liver transplant at a single, large volume United States liver transplant center from January 1, 2013 to December 31, 2014 and died prior to transplant or were delisted for being too ill for transplant were included in this study. We excluded patients delisted due to inadequate social support, medical non-adherence, active substance abuse, or those who were transplanted at another center.

Patient demographics (age, gender, ethnicity, language spoken), etiology of liver disease, Model for End-Stage Liver Disease (MELD) score at time of transplant listing, and education level were received from the United Network for Organ Sharing and Organ Procurement and Transplantation Network registries. Patients' MELD at delisting or death, Child Pugh Score at time of removal, presence of hepatocellular cancer (HCC), and insurance type were collected through review of the electronic health record. Details on the palliative care consultations were also manually reviewed from the electronic medical records.

Descriptive statistics were computed for all continuous variables (age at listing, candidate MELD lab score when being listed for transplant) including means, medians, and interquartile ranges. The rank sum test was used for these continuous variables. Pearson's χ^2^ testing was used for the categorical values (candidate gender, ethnicity, highest education level, and diagnosis) to further compare the baseline characteristics of patients removed from the waiting list *vs* those who remained active. We employed univariable logistic regression to identify factors associated with palliative care consultation with a *P* value cut-off of 0.10. These factors were then evaluated for inclusion in the final multivariable logistic regression model using backwards step-wise elimination, using a *P* value cut-off of 0.05.

This study was approved by the Institutional Review Board of UCSF. Stata, version 12 (Stata Corp., College Station, TX) was used for statistical analyses.

RESULTS
=======

There were 683 patients placed on the liver transplant list in 2013-2014, of which 107 (16%) ultimately dying (*n* = 62) or removed for clinical decompensation prior to liver transplant (*n* = 45). Median age was 58 years and majority (66%) was male. Majority of the patients who died or were de-listed were white (53.3%), followed by Hispanic (22.4%), Asian (12.1%), Black (9.3%), and other (2.8%). The etiology of cirrhosis was alcohol (11%), hepatitis C (41%), alcohol and hepatitis C (20%), and various other etiologies (30%). Majority of these patients had Child-Pugh Class C cirrhosis (60.7%) while 52% of these patients had HCC. In terms of education level, 93.5% had a college degree or less (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics of 107 patients who died or were delisted for being too sick for transplant

                                   ***n* = 107**
  -------------------------------- ---------------
  Age at listing, yr               58 (53-63)
  Male sex                         71 (66%)
  Ethnicity                        
  White                            57 (53.3%)
  Hispanic                         24 (22.4%)
  Asian                            13 (12.1%)
  Black                            10 (9.3%)
  Other                            3 (2.8%)
  MELD at time of listing          16 (12-23)
  Etiology of cirrhosis            
  Alcohol related                  12 (11%)
  Hepatitis C                      44 (41%)
  Alcohol + hepatitis C            21 (20%)
  Other                            30 (28%)
  Child-pugh score at de-listing   
  A                                16 (15%)
  B                                26 (24.3%)
  C                                65 (60.7%)
  HCC                              56 (52%)
  Education level                  
  College degree or less           100 (93.5%)
  Graduate level degree            7 (6.5%)

MELD: Model for end-stage liver disease; HCC: Hepatocellular cancer.

Of these 107 patients who were delisted or died while awaiting transplant, 18 (17%) received a palliative care consult in the 2-year period, of which 89% occurred as inpatients. The median number of days (interquartile range) from palliative care consultation to death was 4 (1-11) d; half of these consultations occurred within 72 h of death and 17% on the same day as death (Figure [1](#F1){ref-type="fig"}). Reasons for palliative care consultation included aiding in transitioning to hospice in 78% of patients, goals of care without transition to comfort care in 11%, and symptom management including refractory ascites, pruritus, and pain in the remaining 11%. Even from the 26 patients with ESLD who were delisted for advanced HCC, just 12% had palliative care consultation.

![Palliative care consultations in patients who died or were delisted over a 24-mo period.](WJT-6-594-g001){#F1}

Patient characteristics associated with palliative care consultation in univariate analysis included younger age (OR = 0.92; *P* \< 0.01), white race (OR = 3.74; *P* = 0.03), and higher MELD at listing (OR = 1.06; *P* = 0.02) and at delisting (OR = 1.05; *P* = 0.01). Subsequent multivariable analysis revealed only younger age (OR = 0.92; *P* = 0.02) and white race (OR = 4.90; *P* = 0.02) remained associated with utilization of palliative care services (Table [2](#T2){ref-type="table"}).

###### 

Factors associated with palliative care consultation, univariable and multivariable logistic regression analysis

  **Factor**                                                  **Univariable analysis**   **Multivariable analysis**                       
  ----------------------------------------------------------- -------------------------- ---------------------------- ------------------- ------
  Age, per year                                               0.92 (0.87-0.98)           \< 0.01                      0.92 (0.87-0.98)    0.02
  Male sex                                                    0.76 (0.27-2.16)           0.61                         \-                  \-
  White race                                                  3.74 (1.14-12.26)          0.03                         4.90 (1.30-18.30)   0.02
  MELD at listing                                             1.06 (1.01-1.12)           0.02                         1.00 (0.97-1.10)    0.39
  MELD at delisting                                           1.05 (1.00-1.10)           0.01                         1.00 (0.97-1.10)    0.34
  Etiology of liver disease                                                                                                               
  Alcohol related                                             Reference                  Reference                                        
  Hepatitis C                                                 0.95 (0.17-5.28)           0.95                         \-                  \-
  Alcohol + hepatitis C                                       1.56 (0.25-9.65)           0.63                                             
  Other                                                       0.77 (0.12-4.88)           0.78                                             
  Child-pugh score at delisting                                                                                                           
  A                                                           Reference                  Reference                                        
  B                                                           0.60 (0.03-10.30)          0.73                         \-                  \-
  C                                                           4.90 (0.60-40.10)          0.14                                             
  HCC                                                         0.89 (0.32-2.46)           0.83                         \-                  \-
  College or lower level of education (*vs* graduate level)   1.23 (0.14-10.9)           0.85                         \-                  \-
  Private insurance (*vs* government)                         0.70 (0.25-1.97)           0.50                         \-                  \-
  English language                                            0.93 (0.24-3.65)           0.92                         \-                  \-

MELD: Model for end-stage liver disease; HCC: Hepatocellular cancer.

DISCUSSION
==========

According to the World Health Organization, palliative care "improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual"\[[@B7]\]. For patients with end-stage liver disease, early integration of palliative care into their routine medical care is particularly crucial to understanding patients' preferences for the end of life, as progressive hepatic encephalopathy often leads to impaired decision-making. Those on the liver transplant list, however, represent a unique sub-group of patients with a "terminal" condition - by virtue of having end-stage liver disease - but await the promise of a cure through liver transplantation. In this setting, palliative care, which traditionally has been considered only for those "at the end of life", may be perceived - by both the patient and providers alike - as unnecessary and unwelcome\[[@B8]-[@B11]\].

Indeed, we observed very low utilization of palliative care services among liver transplant candidates who ultimately died or were delisted for being too sick for liver transplant. Among the 17% of these patients who received palliative care services, half of the consultations occurred within 72 h of death and one in five occurred on the day of death, hardly enough time to develop rapport and aid both patients and their caregivers in the transition to supportive care at the end of life\[[@B12],[@B13]\]. Importantly, we identified two factors - younger age and non-Hispanic white race - that were associated with palliative care consultation. This finding confirms a prior study evaluating barriers to palliative care among older adults that demonstrated that a terminal diagnosis in an elderly patient often is considered an "expectation" rather than a shock compared to that in a younger patient; it is also possible that younger patients at the end of life have more support networks/caretakers at this stage that advocate for improved quality of life\[[@B14],[@B15]\]. Cultural and language barriers likely contribute to underutilization of palliative care services in the non-white population.

In addition, we find it interesting that more than three-fourths of palliative care consultations in our population were to assist with transition to comfort care and just 11% were for aid in symptom management. This depicts how transplant clinicians view palliative care, as a mode to help make patients comfortable at the end of life, but not to facilitate goals of care discussions or to help relieve pain and suffering in a patient population with a terminal condition without transplantation. We recognize the need for integration of palliative care and transplant hepatology teams in efforts to provide comprehensive care for our patients to meet their physical and psychosocial needs even when actively listed for liver transplantation.

We acknowledge that this study is limited by a relatively small sample size; however, it represents the *entire* eligible population at our liver transplant center during the study period, so is an unselected group. Another limitation is that we only evaluated those who died or were delisted rather than all patients on the liver transplant list. This was intentional, as we first wanted to evaluate the uptake of palliative care among those for whom death was certain.

Despite these limitations, this study represents one of the largest to date to evaluate palliative care consultation in the liver transplant population. Poonja et al\[[@B16]\] reported their experience in the liver transplant population at the University of Alberta and noted that of the 102 patients removed from the waitlist or declined over a 5 year period, only 10% were referred to palliative care despite high levels of pain, nausea, and depression. As patients with ESLD have high burden of symptoms, we advocate for increased utilization of palliative care services - for both symptom management and discussions regarding goals of care - and integration of such services early in the liver transplant listing process. Baumann et al\[[@B17]\] confirmed that early palliative care utilization in patients listed for transplantation led to improved symptom management and well-being in this population.

While this study represents a critical first step towards developing interdisciplinary programs directed at providing palliative care to liver transplant candidates, future studies should focus on understanding barriers to early integration of palliative care in the liver transplant population among all ages and ethnicities, in both the inpatient and outpatient setting. In addition, in a prospective study, patient-centered outcomes can be obtained in efforts to show the direct impact of palliative care involvement on the physical and psychosocial well being of these patients. Ultimately the goal should be to facilitate collaboration and, perhaps, even co-management between transplant and palliative care providers for the care of these complex patients - even when the intention to treat is curative - to improve the quality of care and quality of life for patients with cirrhosis awaiting liver transplantation.

COMMENTS
========

Background
----------

Patients with end stage liver disease have 50% 5-year mortality due to complications of cirrhosis and experience a large symptomatic burden including debilitating fatigue, muscle wasting, anorexia, and intractable pruritus. While it is clear that liver transplantation is essentially the only known cure for complications of end-stage liver disease, the ability to receive a transplant can be unpredictable. In patients who do not have access to liver transplant, palliative care services may aid in quality of life of patients and caretakers alike.

Research frontiers
------------------

Though the process of listing individuals for liver transplantation is highly structured, there is no standard of care for the process to transition those who are deemed too sick for liver transplantation to comfort care. Current utilization of palliative care services in liver transplant candidates who did not survive to liver transplant is not largely understood.

Innovations and breakthroughs
-----------------------------

Authors aimed to understand the use of palliative care services in patients with end-stage liver disease who do not have access to liver transplant over a 2-year period and a large volume center. Palliative care services were consulted in less than 20% of patients who were died or removed from the transplant list, majority of which occurred while patients were already hospitalized. In univariable analysis, patients of younger age, white race, and higher model for end-stage liver disease (MELD) scores at time of listing and delisting were more likely to receive palliative care services. Only younger age and Caucasian race were still associated with integration of palliative care services through multivariable analysis. The authors recognize that palliative care services are grossly underutilized in patients who are not deemed transplant candidates.

Applications
------------

While this study represents a critical first step towards developing interdisciplinary programs directed at providing palliative care to liver transplant candidates, future studies should focus on understanding barriers to early integration of palliative care in the liver transplant population. In addition, in a prospective study, patient-centered outcomes can be obtained to show the direct impact of palliative care involvement on the physical and psychosocial well being of these patients. Ultimately the goal should be to facilitate collaboration and, perhaps, even co-management between transplant and palliative care providers for the care of these complex patients - even when the intention to treat is curative - to improve the quality of care and quality of life for patients with cirrhosis awaiting liver transplantation.

Terminology
-----------

Palliative care services encompass more than aiding in transitioning to comfort care and assisting in goals of care discussions, and can be particularly helpful in symptom management, even in patients who are not terminally ill. The laboratory based MELD score accounts for patients' bilirubin, international normalized ratio (INR), and creatinine levels and was calculated both at time of transplant listing and delisting. The child pugh score entails a combination of laboratory (bilirubin, albumin, INR) and clinical (presence of ascites, encephalopathy) factors; though it was originally used to predict mortality in cirrhotics at the time of surgery, if can also aid in understanding the severity of liver disease.

Peer-review
-----------

This is an integral single center retrospective study that aims to shed light on the need for integration of palliative care into the liver transplant population, even when the intent to treat is curative, in efforts to improve their quality of life.
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